Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1903 2
1906 1
1908 1
1910 2
1912 1
1915 2
1921 1
1922 1
1924 1
1925 1
1931 1
1940 1
1943 1
1944 1
1946 1
1947 2
1948 2
1949 1
1950 5
1951 1
1952 4
1953 6
1954 3
1955 2
1957 4
1958 2
1959 2
1961 3
1962 2
1963 4
1964 1
1965 2
1966 2
1967 3
1968 5
1969 4
1970 3
1971 7
1972 4
1973 1
1974 2
1975 6
1976 2
1977 6
1978 4
1979 6
1980 6
1981 6
1982 8
1983 3
1984 2
1985 3
1986 4
1987 5
1988 8
1989 5
1990 2
1991 2
1992 6
1993 10
1994 4
1995 7
1996 11
1997 8
1998 14
1999 11
2000 14
2001 17
2002 12
2003 23
2004 18
2005 25
2006 15
2007 22
2008 16
2009 22
2010 15
2011 11
2012 23
2013 15
2014 20
2015 16
2016 14
2017 20
2018 10
2019 11
2020 17
2021 11
Text availability
Article attribute
Article type
Publication date

Search Results

573 results
Results by year
Filters applied: . Clear all
Page 1
Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis.
Baeten D, Sieper J, Braun J, Baraliakos X, Dougados M, Emery P, Deodhar A, Porter B, Martin R, Andersson M, Mpofu S, Richards HB; MEASURE 1 Study Group; MEASURE 2 Study Group. Baeten D, et al. Among authors: richards hb. N Engl J Med. 2015 Dec 24;373(26):2534-48. doi: 10.1056/NEJMoa1505066. N Engl J Med. 2015. PMID: 26699169 Free article. Clinical Trial.
Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis.
Mease PJ, McInnes IB, Kirkham B, Kavanaugh A, Rahman P, van der Heijde D, Landewé R, Nash P, Pricop L, Yuan J, Richards HB, Mpofu S; FUTURE 1 Study Group. Mease PJ, et al. Among authors: richards hb. N Engl J Med. 2015 Oct;373(14):1329-39. doi: 10.1056/NEJMoa1412679. N Engl J Med. 2015. PMID: 26422723 Free article. Clinical Trial.
Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial.
McInnes IB, Mease PJ, Kirkham B, Kavanaugh A, Ritchlin CT, Rahman P, van der Heijde D, Landewé R, Conaghan PG, Gottlieb AB, Richards H, Pricop L, Ligozio G, Patekar M, Mpofu S; FUTURE 2 Study Group. McInnes IB, et al. Among authors: richards h. Lancet. 2015 Sep 19;386(9999):1137-46. doi: 10.1016/S0140-6736(15)61134-5. Epub 2015 Jun 28. Lancet. 2015. PMID: 26135703 Free article. Clinical Trial.
Improvement of Signs and Symptoms of Nonradiographic Axial Spondyloarthritis in Patients Treated With Secukinumab: Primary Results of a Randomized, Placebo-Controlled Phase III Study.
Deodhar A, Blanco R, Dokoupilová E, Hall S, Kameda H, Kivitz AJ, Poddubnyy D, van de Sande M, Wiksten AS, Porter BO, Richards HB, Haemmerle S, Braun J. Deodhar A, et al. Among authors: richards hb. Arthritis Rheumatol. 2021 Jan;73(1):110-120. doi: 10.1002/art.41477. Epub 2020 Nov 24. Arthritis Rheumatol. 2021. PMID: 32770640 Free PMC article. Clinical Trial.
Modified stoke ankylosing spondylitis spinal score as an outcome measure to assess the impact of treatment on structural progression in ankylosing spondylitis.
van der Heijde D, Braun J, Deodhar A, Baraliakos X, Landewé R, Richards HB, Porter B, Readie A. van der Heijde D, et al. Among authors: richards hb. Rheumatology (Oxford). 2019 Mar 1;58(3):388-400. doi: 10.1093/rheumatology/key128. Rheumatology (Oxford). 2019. PMID: 29860356 Free PMC article. Review.
Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study.
Braun J, Baraliakos X, Deodhar A, Baeten D, Sieper J, Emery P, Readie A, Martin R, Mpofu S, Richards HB; MEASURE 1 study group. Braun J, et al. Among authors: richards hb. Ann Rheum Dis. 2017 Jun;76(6):1070-1077. doi: 10.1136/annrheumdis-2016-209730. Epub 2016 Dec 13. Ann Rheum Dis. 2017. PMID: 27965257 Free article. Clinical Trial.
Secukinumab 150/300 mg Provides Sustained Improvements in the Signs and Symptoms of Active Ankylosing Spondylitis: 3-Year Results from the Phase 3 MEASURE 3 Study.
Pavelka K, Kivitz AJ, Dokoupilova E, Blanco R, Maradiaga M, Tahir H, Wang Y, Porter BO, Stefanska A, Richards HB, Rohrer S; MEASURE 3 study group. Pavelka K, et al. Among authors: richards hb. ACR Open Rheumatol. 2020 Feb;2(2):119-127. doi: 10.1002/acr2.11102. Epub 2020 Jan 20. ACR Open Rheumatol. 2020. PMID: 31957970 Free PMC article.
European S3-guidelines on the systemic treatment of psoriasis vulgaris.
Pathirana D, Ormerod AD, Saiag P, Smith C, Spuls PI, Nast A, Barker J, Bos JD, Burmester GR, Chimenti S, Dubertret L, Eberlein B, Erdmann R, Ferguson J, Girolomoni G, Gisondi P, Giunta A, Griffiths C, Hönigsmann H, Hussain M, Jobling R, Karvonen SL, Kemeny L, Kopp I, Leonardi C, Maccarone M, Menter A, Mrowietz U, Naldi L, Nijsten T, Ortonne JP, Orzechowski HD, Rantanen T, Reich K, Reytan N, Richards H, Thio HB, van de Kerkhof P, Rzany B. Pathirana D, et al. Among authors: richards h. J Eur Acad Dermatol Venereol. 2009 Oct;23 Suppl 2:1-70. doi: 10.1111/j.1468-3083.2009.03389.x. J Eur Acad Dermatol Venereol. 2009. PMID: 19712190
Nucleus accumbens D2/3 receptors predict trait impulsivity and cocaine reinforcement.
Dalley JW, Fryer TD, Brichard L, Robinson ES, Theobald DE, Lääne K, Peña Y, Murphy ER, Shah Y, Probst K, Abakumova I, Aigbirhio FI, Richards HK, Hong Y, Baron JC, Everitt BJ, Robbins TW. Dalley JW, et al. Among authors: richards hk. Science. 2007 Mar 2;315(5816):1267-70. doi: 10.1126/science.1137073. Science. 2007. PMID: 17332411 Free PMC article.
Secukinumab efficacy in anti-TNF-naive and anti-TNF-experienced subjects with active ankylosing spondylitis: results from the MEASURE 2 Study.
Sieper J, Deodhar A, Marzo-Ortega H, Aelion JA, Blanco R, Jui-Cheng T, Andersson M, Porter B, Richards HB; MEASURE 2 Study Group. Sieper J, et al. Among authors: richards hb. Ann Rheum Dis. 2017 Mar;76(3):571-592. doi: 10.1136/annrheumdis-2016-210023. Epub 2016 Aug 31. Ann Rheum Dis. 2017. PMID: 27582421 Clinical Trial.
573 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page